Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2025

Monica M Lahra; Tiffany R Hogan; National Neisseria Network

doi:10.33321/cdi.2025.49.045

Meningococcal Surveillance Australia: Reporting period 1 January to 31 March 2025

Commun Dis Intell (2018). 2025 Jul 30:49. doi: 10.33321/cdi.2025.49.045.

Authors

Monica M Lahra^{1

2}, Tiffany R Hogan¹; National Neisseria Network

Affiliations

¹ The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia.
² School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW 2052, Australia.

PMID: 40738153
DOI: 10.33321/cdi.2025.49.045

Abstract

Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.

Keywords: Neisseria meningitidis; antimicrobial resistance; disease surveillance; invasive meningococcal disease.

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Australia / epidemiology
Ceftriaxone / pharmacology
Ciprofloxacin / pharmacology
Disease Notification
Drug Resistance, Bacterial
Humans
Meningococcal Infections* / epidemiology
Meningococcal Infections* / history
Meningococcal Infections* / microbiology
Neisseria meningitidis* / classification
Neisseria meningitidis* / drug effects
Neisseria meningitidis* / isolation & purification
Population Surveillance*
Rifampin / pharmacology
Serogroup

Substances

Anti-Bacterial Agents
Ciprofloxacin
Ceftriaxone
Rifampin